Clinical trial · Observational
LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib
Local AblativeTherapy for Oligoprogressive Non-Small-Cell Lung Cancer Treated With First-line OSImertinib
NCT04216121CI-TRIAL-00078439LAT-FLOSIunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine whether in patients with EGFR mutated advanced NSCLC and osimertinib as first-line treatment, the (repeated) use of LAT to ≤ 3 OP lesions and continuation of first-line osimertinib, improves the median progression-free survival by more than 3 months (i.e. PFS2-PFS1 = \>3 months).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Local ablative therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- PFS 2
- timeFrame
- Time from start of osimertinib until first PD after LAT or death whichever comes first, up to 3 year after LAT
- description
- Progression Free Survival 2
Secondary outcomes (4)
- measure
- Time to next line systemic therapy
- timeFrame
- Time from LAT until initiation of next line systemic therapy or death whichever comes first, up to 3 years after LAT
- measure
- Patterns of disease progression
- timeFrame
- Time from LAT until disease progression or death whichever comes first, up to 3 years after LAT
- description
- Patterns of disease progression after local ablative therapy (LAT) identified on sequential CT scans taken at 3 monthly intervals to document the natual history of the disease after LAT
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or female, ≥ 18 years of age 2. Established histological diagnosis of advanced NSCLC, not suitable for radical treatment, with an EGFR actionable mutation receiving first-line targeted TKI therapy with osimertinib 3. Initial radiologically confirmed response (at least stable disease) to osimertinib assessed 3 months post commencing osimertinib according to RECIST criteria v1.1. 4. Confirmed OPD defined as ≤ 3 intra- and extracranial sites of progressive disease. OP may be defined as progression of an individual metastasis according to RECIST or on 2 consecutive imaging studies at least 2 months apart with a minimum of 5mm increase in size from baseline or an unambiguous development of a new metastatic lesion with a grand total of 3 lesions. All sites must be visible, imaging defined targets, not previously treated with radiation or radiofrequency and suitable for treatment with LAT as determined by the local multi-disciplinary team (MDT). 5. Adequate baseline organ function to allow LAT to all the OP targets. 6. Predicted life expectancy ≥ 6 months 7. Karnofsky Index ≥ 60% and ECOG 0-2 8. Provision of written informed consent 9. Female participants must be surgically sterile or postmenopausal if SBRT is planned to the abdominal area or must agree to use effective contraception during the period of therapy. Exclusion Criteria: 1. \> 3 sites of progressive disease 2. Oligoprogressive metastases not amenable to LAT 3. Radiotherapy or radiofrequency ablation near the OP lesion prior to the inclusion in the LAT-FLOSI study 4. Co-morbidities considered clinically precluding the safe use of LAT 5. Any psychological, sociological or geographical issue potentially hampering compliance with the study 6. Pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.